Entity Central Index Key
Cover [Abstract]
Document Type
Document Type
Amendment Flag
Amendment Flag
Document Period End Date
Document Period End Date
Document Fiscal Year Focus
Document Fiscal Year Focus
Document Fiscal Period Focus
Document Fiscal Period Focus
Trading Symbol
Trading Symbol
Title of 12(b) Security
Security12b Title
Security Exchange Name
Security Exchange Name
Entity Registrant Name
Entity Registrant Name
Entity Central Index Key
Current Fiscal Year End Date
Current Fiscal Year End Date
Entity Well-known Seasoned Issuer
Entity Well Known Seasoned Issuer
Entity Current Reporting Status
Entity Current Reporting Status
Entity Interactive Data Current
Entity Interactive Data Current
Entity Voluntary Filers
Entity Voluntary Filers
Entity Filer Category
Entity Filer Category
Entity Public Float
Entity Public Float
Entity Common Stock, Shares Outstanding
Entity Common Stock Shares Outstanding
Entity Shell Company
Entity Shell Company
Entity Small Business
Entity Small Business
Entity Emerging Growth Company
Entity Emerging Growth Company
ICFR Auditor Attestation Flag
Icfr Auditor Attestation Flag
Entity Incorporation, State or Country Code
Entity Incorporation State Country Code
Entity File Number
Entity File Number
Entity Tax Identification Number
Entity Tax Identification Number
Entity Address, Address Line One
Entity Address Address Line1
Entity Address, Address Line Two
Entity Address Address Line2
Entity Address, City or Town
Entity Address City Or Town
Entity Address, State or Province
Entity Address State Or Province
Entity Address, Postal Zip Code
Entity Address Postal Zip Code
City Area Code
City Area Code
Local Phone Number
Local Phone Number
Document Annual Report
Document Annual Report
Document Transition Report
Document Transition Report
Documents Incorporated by Reference
Documents Incorporated By Reference [Text Block]
Clinical trial deposit current.
Clinical trial deposit non current.
Milestone payment liability.
Statement Of Financial Position [Abstract]
Statement [Table]
Statement [Table]
Class of Stock
Statement Class Of Stock [Axis]
Class of Stock
Class Of Stock [Domain]
Preferred Stock Series A
Series A Preferred Stock [Member]
Preferred Stock Series B
Series B Preferred Stock [Member]
Preferred Stock Series C
Series C Preferred Stock [Member]
Statement [Line Items]
Statement [Line Items]
Assets
Assets [Abstract]
Current assets
Assets Current [Abstract]
Cash and cash equivalents
Cash And Cash Equivalents At Carrying Value
Prepaid expenses, deposits and other
Prepaid Expense Current
Clinical trial deposit
Clinical Trial Deposit Current
Deferred loan costs
Deferred Costs Current
Total current assets
Assets Current
Clinical trial deposit
Clinical Trial Deposit Non Current
Property, equipment and intangibles - net
Property Plant And Equipment Net
Deferred financing costs
Deferred Costs
Total assets
Assets
Liabilities and stockholders' equity
Liabilities And Stockholders Equity [Abstract]
Liabilities
Liabilities [Abstract]
Current liabilities
Liabilities Current [Abstract]
Accounts payable and accrued liabilities
Accounts Payable And Accrued Liabilities Current
Related party payables
Due To Related Parties Current
Total current liabilities
Liabilities Current
Milestone payment liability
Milestone Payment Liability
Total liabilities
Liabilities
Stockholders’ equity
Stockholders Equity [Abstract]
Preferred stock
Preferred Stock Value
Common stock Authorized 175,000 shares at June 30, 2021 (June 30, 2020 - 95,000) $0.001 par value 32,740 issued at June 30, 2021 (June 30, 2020 – 11,458)
Common Stock Value
Additional paid-in capital
Additional Paid In Capital Common Stock
Accumulated deficit
Retained Earnings Accumulated Deficit
Accumulated other comprehensive income
Accumulated Other Comprehensive Income Loss Net Of Tax
Total stockholders’ equity
Stockholders Equity
Total liabilities and stockholders’ equity
Liabilities And Stockholders Equity
Preferred stock, shares authorized
Preferred Stock Shares Authorized
Preferred stock, par value
Preferred Stock Par Or Stated Value Per Share
Preferred Stock, shares issued
Preferred Stock Shares Issued
Preferred stock, shares outstanding
Preferred Stock Shares Outstanding
Common stock, shares authorized
Common Stock Shares Authorized
Common stock, par value
Common Stock Par Or Stated Value Per Share
Common stock, shares issued
Common Stock Shares Issued
Merger costs.
In-progress research and development expense.
Income Statement [Abstract]
Expenses
Operating Expenses [Abstract]
Research and development
Research And Development Expense
General and administrative
General And Administrative Expense
Merger costs
Merger Costs
In-process research and development
In Progress Research And Development Expense
Operating expenses
Operating Expenses
Other income (loss)
Nonoperating Income Expense [Abstract]
Foreign exchange
Foreign Currency Transaction Gain Loss Before Tax
Amortization of deferred loan costs
Other Amortization Of Deferred Charges
Interest - net
Other Operating Income Expense Net
Other loss (income)
Nonoperating Income Expense
Net loss for the year
Net Income Loss
Computation of basic loss per share
Earnings Per Share Basic And Diluted [Abstract]
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance
Dividends Preferred Stock Stock
Series A Preferred cash dividend
Dividends Preferred Stock Cash
Series B Preferred stock dividend
Preferred Stock Dividends And Other Adjustments
Net loss for the year attributable to common stockholders
Net Income Loss Available To Common Stockholders Basic
Basic and fully diluted loss per share
Earnings Per Share Basic
Basic and fully diluted weighted average number of shares
Weighted Average Number Of Shares Outstanding Basic
Shares issuance of warrants during the period.
issuance of shares and warrants net of issue cost
Exercise of pre funded warrants for cash shares.
Exercise of pre funded warrants for cash.
Exercise of warrants for cash, Shares.
Exercise of warrants for cash.
Conversion of Series B preferred stock to common stock shares.
Conversion of series B preferred stock to common stock.
Series a preferred stock dividend.
Number of shares issued for series B preferred stock dividend.
Series B preferred stock dividend.
Adgero merger shares.
Adgero merger value.
Issuance of series C preferred stock.
Series C placement agent warrants
Series C preferred stock issue costs.
Dividends recognized on beneficial conversion of preferred stock price increase (decrease).
Conversion of Series C preferred stock to common stock shares.
Conversion of series C preferred stock to common stock.
Series C agent warrants exercise.
Statement Of Stockholders Equity [Abstract]
Equity Components
Statement Equity Components [Axis]
Equity Component
Equity Component [Domain]
Common stock
Common Stock [Member]
Additional paid-in capital
Additional Paid In Capital [Member]
Accumulated other comprehensive income
Accumulated Other Comprehensive Income [Member]
Preferred stock
Preferred Stock [Member]
Accumulated deficit
Retained Earnings [Member]
Beginning Balance
Beginning Balance, shares
Shares Outstanding
Issuance of shares and warrants - net of issue costs
Issuance Of Shares And Warrants Net Of Issue Cost
Issuance of shares and warrants - net of issue costs, shares
Issuance Of Shares And Warrants Net Of Issue Cost Share
Adgero merger (note 3)
Adgero Merger Value
Adgero merger, shares
Adgero Merger Shares
Issuance of Series C Preferred stock
Issuance Of Series C Preferred Stock
Series C placement agent warrants
Series C Placement Agent Warrants
Series C Preferred stock share issuance costs
Series C Preferred Stock Issue Costs
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance
Dividends Recognized On Beneficial Conversion Of Preferred Stock Price Increase Decrease
Exercise of pre-funded warrants for cash
Exercise Of Pre Funded Warrants For Cash
Exercise of pre-funded warrants for cash, shares
Exercise Of Pre Funded Warrants For Cash Shares
Exercise of warrants for cash
Exercise Of Warrants For Cash
Exercise of warrants for cash, shares
Exercise Of Warrants For Cash Shares
Conversion of Series B preferred stock to common stock
Conversion Of Seriesb Preferred Stock To Common Stock
Conversion of Series B preferred stock to common stock, shares
Conversion Of Series B Preferred Stock To Common Stock Shares
Conversion of Series C Preferred stock to common stock
Conversion Of Series C Preferred Stock To Common Stock
Conversion of Series C preferred stock to common stock, shares
Conversion Of Series C Preferred Stock To Common Stock Share
Series C Agent Warrants exercised
Series C Agent Warrants Exercised
Shares issued for services
Stock Issued During Period Value Issued For Services
Shares issued for services, shares
Stock Issued During Period Shares Issued For Services
Warrants issued for services
Adjustment Of Warrants Granted For Services
Stock options exercised
Stock Issued During Period Value Stock Options Exercised
Stock options exercised, Shares
Stock Issued During Period Shares Stock Options Exercised
Stock option expense
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
Series A preferred cash dividend
Series Preferred Stock Dividends
Series B preferred stock dividend
Seriesb Preferred Stock Dividend
Series B preferred stock dividend, shares
Seriesb Preferred Stock Dividend Shares
Loss for the year
Profit Loss
Ending Balance
Ending Balance, shares
Gain loss from change in fair value of milestone liability.
The amount of amortization charged against earnings during the period for deferred loan costs.
Fair value of share-based compensation granted to nonemployees as payment for services rendered.
Amount of expense related to changes in fair value of warrants issued for services.
Increase (decrease) in clinical trial deposits.
Proceeds from issuance of shares and warrants.
Statement Of Cash Flows [Abstract]
Cash flows from operating activities
Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]
Adjustments to reconcile net loss to net cash used in operating activities
Adjustments Noncash Items To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]
Amortization of intangible assets
Amortization Of Intangible Assets
Depreciation of property and equipment
Depreciation
Impairment of in-process research and development
Change in fair value of milestone liability
Gain Loss From Change In Fair Value Of Milestone Liability
Interest expense
Interest Expense
Amortization of deferred loan costs
Amortization Of Deferred Loan Costs
Shares issued for services
Issuance Of Stock For Services
Warrants issued for services
Increase Decrease In Fair Value Of Warrants Issued For Services
Stock option expense
Stock Option Plan Expense
Changes in operating assets and liabilities
Increase Decrease In Operating Capital [Abstract]
Prepaid expenses, deposits and other
Increase Decrease In Prepaid Expenses Other
Clinical trial deposits
Increase Decrease In Clinical Trial Deposits
Accounts payable and accrued liabilities
Increase Decrease In Accounts Payable And Accrued Liabilities
Related party payables
Increase Decrease In Due To Related Parties
Net cash used in operating activities
Net Cash Provided By Used In Operating Activities
Cash flows from investing activities
Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]
Cash acquired on merger with Adgero
Cash Acquired From Acquisition
Purchase of equipment
Payments To Acquire Machinery And Equipment
Proceeds on sale of equipment
Proceeds From Sale Of Machinery And Equipment
Net cash provided by investing activities
Net Cash Provided By Used In Investing Activities
Cash flows from financing activities
Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]
Net proceeds from the issuance of shares and warrants
Proceeds From Issuance Of Shares And Warrants
Warrants exercised for cash
Proceeds From Warrant Exercises
Stock options exercised for cash
Proceeds From Stock Options Exercised
Proceeds from loan
Proceeds From Construction Loans Payable
Repayment of loan
Repayments Of Debt
Interest paid
Interest Paid
Deferred financing costs
Payments Of Financing Costs
Series A preferred cash dividend
Payments Of Dividends Preferred Stock And Preference Stock
Net cash provided by financing activities
Net Cash Provided By Used In Financing Activities
Increase (decrease) in cash and cash equivalents
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
Cash and cash equivalents – beginning of year
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
Cash and cash equivalents – end of year
Supplementary information (note 11)
Supplemental Cash Flow Information Related Text
Organization Consolidation And Presentation Of Financial Statements [Abstract]
Nature of operations, corporate history, and going concern and management plans
Nature Of Operations
Accounting Policies [Abstract]
Significant accounting policies
Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]
Business Combinations [Abstract]
Merger
Mergers Acquisitions And Dispositions Disclosures [Text Block]
Clinical trial deposit.
Other Liabilities [Abstract]
Clinical Trial Deposit
Clinical Trial Deposit Disclosure [Text Block]
Property plant and equipment and intangibles assets disclosure text block.
Property Plant And Equipment [Abstract]
Property Equipment and Intangibles
Property Plant And Equipment And Intangibles Assets Disclosure [Text Block]
Related Party Transactions [Abstract]
Related party transactions
Related Party Transactions Disclosure [Text Block]
Loans Payable [Abstract]
Loan from National Brain Tumor Society and National Foundation for Cancer Research
Debt Disclosure [Text Block]
Equity [Abstract]
Stockholders' Equity
Stockholders Equity Note Disclosure [Text Block]
Income Tax Disclosure [Abstract]
Income Taxes
Income Tax Disclosure [Text Block]
Commitments And Contingencies Disclosure [Abstract]
Commitments and contingencies
Commitments And Contingencies Disclosure [Text Block]
Supplemental Cash Flow Elements [Abstract]
Supplementary statement of cash flows information
Cash Flow Supplemental Disclosures [Text Block]
Risks And Uncertainties [Abstract]
Financial Risk Management
Concentration Risk Disclosure [Text Block]
Subsequent Events [Abstract]
Subsequent events
Subsequent Events [Text Block]
Basis of Presentation
Basis Of Accounting Policy Policy [Text Block]
Consolidation
Consolidation Policy [Text Block]
Use of Estimates
Use Of Estimates
Cash and Cash Equivalents
Cash And Cash Equivalents Policy [Text Block]
Foreign Currency Translation
Foreign Currency Transactions And Translations Policy [Text Block]
Acquired in-process research and development expense.
Acquired In-process Research And Development Expense
Acquired In Process Research And Development Expense Policy [Text Block]
Property, Plant and Equipment, Policy
Property Plant And Equipment Policy [Text Block]
Income Taxes
Income Tax Policy [Text Block]
Financial Instruments
Fair Value Of Financial Instruments Policy
Intangible Assets
Goodwill And Intangible Assets Policy [Text Block]
Accruals For Research And Development Expenses And Clinical Trials .
Accruals for Research and Development Expenses and Clinical Trials
Accruals For Research And Development Expenses And Clinical Trials Policytext Block
Discloure of accounting policy for warrant and shares for services.
Warrants and Shares Issued For Services
Warrants And Shares Issued For Services Policy [Text Block]
Stock Options
Share Based Compensation Option And Incentive Plans Policy
Loss Per Share
Earnings Per Share Policy [Text Block]
Segment Information
Segment Reporting Policy Policy [Text Block]
Recent Accounting Pronouncements
New Accounting Pronouncements Policy Policy [Text Block]
Schedule of Consideration Transferred Stockholders, Recognized Identified Assets Acquired and Liabilities Assumed Under Merger
Schedule Of Recognized Identified Assets Acquired And Liabilities Assumed Table [Text Block]
Schedule of milestone payment liability.
Schedule Of Milestone Payment Liability
Schedule Of Milestone Payment Liability Table [Text Block]
Schedule of property equipment and intangibles assets table text block.
Schedule of Property Equipment and Intangibles
Schedule Of Property Equipment And Intangibles Assets Table [Text Block]
Loan Table Text Block.
Summary of Loan
Loan Table [Text Block]
Schedule of issuance of preferred stock.
Schedule Of Stock By Class [Table]
Schedule Of Stock By Class [Table]
Performance stock units.
Performance stock units [Member]
Performance Stock Units [Member]
Award Type
Award Type [Axis]
Award Type
Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]
Stock options [Member]
Employee Stock Option [Member]
Class of Warrant or Right
Class Of Warrant Or Right [Axis]
Class of Warrant or Right
Class Of Warrant Or Right [Domain]
Series c warrants.
Series C Warrants [Member]
Series C Warrants [Member]
Class Of Stock [Line Items]
Class Of Stock [Line Items]
Schedule of Issuance of Series C Preferred Stock
Schedule Of Issuance Of Preferred Stock Table [Text Block]
Schedule of Series C Preferred Stock Outstanding, Conversion Shares and Future Dividends
Schedule Of Preferred Units [Text Block]
Schedule of Conversion of Series B Preferred Stock to Common Stock
Schedule Of Common Stock Outstanding Roll Forward Table [Text Block]
Schedule of Outstanding Under the Legacy Plan
Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]
Summary of Stock Options Currently Outstanding and Exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding And Exercisable Table [Text Block]
Schedule of Valuation Assumptions Using a Black-Scholes Pricing Model
Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]
Schedule of Stock Option Expense
Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]
Schedule of Unvested Stock Options
Schedule Of Nonvested Share Activity Table [Text Block]
Schedule of Warrants
Schedule Of Stockholders Equity Note Warrants Or Rights [Text Block]
Schedule of outstanding warrants.
Schedule of Changes in Outstanding Warrants
Schedule Of Outstanding Warrants Table [Text Block]
Schedule of conversion of preferred stock to warrants.
Schedule of Conversion of Series C Preferred Stock to Series C Warrants
Schedule Of Conversion Of Preferred Stock To Warrants Table [Text Block]
Components of Future Tax Assets and Deferred Tax Liabilities
Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]
Schedule of Difference Between Income Tax Rate and Statutory Income Tax Rate
Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]
Schedule of Supplementary Statement of Cash Flows Information
Schedule Of Cash Flow Supplemental Disclosures Table [Text Block]
Schedule of Balances in Foreign Currencies
Schedule Of Intercompany Foreign Currency Balances [Text Block]
Schedule of Fair Value of Off-Balance Sheet Risks
Schedule Of Fair Value Off Balance Sheet Risks [Text Block]
Substantial doubt about companys ability to continues going concern period.
Proceeds from registered direct financing subsequent.
Net loss
Negative cash flow from operations
Cash and cash equivalents
Proceeds from registered direct financing subsequent
Proceeds From Registered Direct Financing Subsequent
Substantial Doubt about Companys Ability to Continues Going Concern Period
Substantial Doubt About Companys Ability To Continues Going Concern Period
Significant Accounting Policies Textual [Abstract]
Long-Lived Tangible Asset
Property Plant And Equipment By Type [Axis]
Long-Lived Tangible Asset
Property Plant And Equipment Type [Domain]
Website Development Costs [Member]
Software Development [Member]
Warrant [Member]
Warrant [Member]
Antidilutive Securities
Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]
Antidilutive Securities, Name
Antidilutive Securities Name [Domain]
Series C Preferred share warrants member.
Series C Preferred Share Warrants [Member]
Series C Preferred Share Warrants [Member]
Series B Convertible Preferred Shares [Member]
Series B Convertible Preferred Shares [Member]
Series B Convertible Preferred Shares [Member]
Series C convertible preferred shares.
Series C Convertible Preferred Shares [Member]
Series C Convertible Preferred Shares [Member]
Significant Accounting Policies (Textual)
Significant Accounting Policies Textual [Abstract]
Property and equipment estimated useful life
Property Plant And Equipment Estimated Useful Lives
Additional uncertain tax provisions
Liability For Uncertain Tax Positions Noncurrent
Amortization of website development costs
Finite Lived Intangible Asset Useful Life
Anti-dilutive warrants, stock options, performance stock units, and convertible preferred shares related to outstanding
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
Number of operating segments
Number Of Operating Segments
Number of reportable segments
Number Of Reportable Segments
Business acquisition, stock purchase warrants.
Business acquisition, class of warrant exercisable price.
Business acquisition equity interests issued or issuable number of shares issued as merger fee.
Weighted average risk free interest rate.
Weighted average remaining term.
Volatility rate.
Common stock dividends percentage.
Schedule Of Business Acquisitions By Acquisition Equity Interest Issued Or Issuable [Table]
Schedule Of Business Acquisitions By Acquisition Equity Interest Issued Or Issuable [Table]
Business Acquisition
Business Acquisition [Axis]
Business Acquisition, Acquiree
Business Acquisition Acquiree [Domain]
Merger Agreement [Member]
Merger Agreement [Member]
Merger Agreement [Member]
Equity Interest Type
Equity Interest Issued Or Issuable By Type [Axis]
Equity Interest Issued or Issuable, Type
Equity Interest Issued Or Issuable Type [Domain]
Sale of Stock
Subsidiary Sale Of Stock [Axis]
Sale of Stock
Sale Of Stock Name Of Transaction [Domain]
Private Placement [Member]
Private Placement [Member]
REM-001 Therapy Member.
REM-001 Therapy [Member]
R E M001 Therapy [Member]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Business Acquisition Equity Interests Issued Or Issuable [Line Items]
Number of shares issued
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued
Stock purchase warrants
Business Acquisition Stock Purchase Warrants
Warrants exercisable price
Business Acquisition Class Of Warrant Exercisable Price
Merger success fee
Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued As Merger Fee
Weighted Average Risk Free Interest Rate
Weighted Average Risk Free Interest Rate
Weighted Average Remaining Term
Weighted Average Remaining Term
Volatility Rate
Volatility Rate
Dividend rate
Common Stock Dividends Percentage
Merger success fee share price
Business Acquisition Share Price
Legal fee
Legal Fees
Business combination, recognized identifiable assets acquired and liabilities assumed, current liabilities, In-process research and development.
Net assets acquired abstract.
Success Fee Shares [Member]
Success Fee Shares [Member]
Success Fee Shares [Member]
Consideration:
Business Combination Consideration Transferred [Abstract]
Common stock
Business Combination Consideration Transferred1
Net assets acquired:
Net Assets Acquired [Abstract]
Cash
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Cash And Equivalents
Other current assets
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Other
Property and equipment (note 5)
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Property Plant And Equipment
Accounts payable and accrued liabilities
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Accounts Payable
Milestone payment liability
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities Other
In-process research and development
Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Liabilities In Process Research And Development
Cash or equivalent to common stock
Payments To Acquire Businesses Gross
Contingent amounts payable to St. Cloud
Business Combination Contingent Consideration Liability
Cash paid to employees
Payments To Employees
Milestone payment liability addition.
Milestone payment liability change in fair value estimate.
Balance – June 30, 2020
Addition
Milestone Payment Liability Addition
Change in fair value estimate
Milestone Payment Liability Change In Fair Value Estimate
Balance – June 30, 2021
Payments related to patient enrollment milestones.
Patient enrollment milestones payments
Patient Enrollment Milestones Payments
Deposit payments.
deposit payment expensed.
Remainder of deposits payments anticipated to future invoice.
Deposits payments anticipated short term.
Deposits payments anticipated long term.
Deposits payments
Deposits Payments
Deposit payment expensed
Deposit Payment Expensed
Remainder of Deposits payments anticipated to future invoice
Remainder Of Deposits Payments Anticipated To Future Invoice
Deposits payments anticipated in near term
Deposits Payments Anticipated Short Term
Deposits payments anticipated beyond twelve months
Deposits Payments Anticipated Long Term
Accumulated depreciation depletion and amortization property plant and equipment and intangibles assets.
Property equipment and intangibles assets gross.
Property equipment and intangibles assets.
Schedule Of Property Plant And Equipment [Table]
Schedule Of Property Plant And Equipment [Table]
Acquired in adgero merger.
Acquired in Adgero Merger [Member]
Acquired In Adgero Merger [Member]
Laboratory equipment purchased.
Laboratory Equipment Purchased [Member]
Laboratory Equipment Purchased [Member]
Disposal of furniture.
Disposal of Furniture [Member]
Disposal Of Furniture [Member]
Property Plant And Equipment [Line Items]
Property Plant And Equipment [Line Items]
Beginning Balance
Property Equipment And Intangibles Assets
Property and equipment, gross
Property Equipment And Intangibles Assets Gross
Less depreciation and amortization
Accumulated Depreciation Depletion And Amortization Property Plant And Equipment And Intangibles Assets
Ending Balance
Capitalized cost
Payments For Software
Amortization expense
Adjustment For Amortization
Legal Entity
Legal Entity [Axis]
Entity
Entity [Domain]
Valent Technologies LLC [Member]
Valent Technologies LLC [Member]
Valent Technologies L L C [Member]
Loan payable outstanding amount
Loans Payable Current
Aggregate accrued interest
Interest Payable Current
Preferred stock, rate of dividend
Preferred Stock Dividend Rate Percentage
Dividend payable
Funding.
Payment of principal and interest.
Schedule Of Guarantee Obligations [Table]
Schedule Of Guarantee Obligations [Table]
Counterparty Name
Counterparty Name [Axis]
Counterparty Name
Repurchase Agreement Counterparty Name [Domain]
National Brain Tumor Society and the National Foundation for Cancer Research Member.
N B T S and N F C R [Member]
N B T S And N F C R [Member]
Guarantee Obligations [Line Items]
Guarantee Obligations [Line Items]
Balance – June 30, 2020
Loans Payable
Funding
Funding
Amortization of deferred financing costs
Payment of principal and interest
Payment Of Principal And Interest
Balance – June 30, 2021
Warrants issued.
Repayment of loan.
Repayment of loan interest.
National brain tumor society and national foundation for cancer research.
National Brain Tumor Society and National Foundation for Cancer Research [Member]
National Brain Tumor Society And National Foundation For Cancer Research [Member]
National brain tumor society.
National Brain Tumor Society [Member]
National Brain Tumor Society [Member]
Short-term Debt, Type
Short Term Debt Type [Axis]
Short-term Debt, Type
Short Term Debt Type [Domain]
Promissory note.
Promissory Note [Member]
Promissory Note [Member]
Loan received
Proceeds From Issuance Of Long Term Debt
Warrants issued
Warrants Issued
Warrants exercise price
Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1
Accrued interest rate
Debt Instrument Interest Rate Stated Percentage
Debt, maturity date
Debt Instrument Maturity Date
Repayment of loan
Repayment Of Loan
Repayment of loan interest
Repayment Of Loan Interest
Risk-free interest rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
Volatility Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
Expected Term
Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
Dividend Rate
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
Number of new temporary stock issued during the period.
Issued on exercise of Series C preferred agent warrants, shares.
Issued on exercise of Series C preferred agent warrants.
Conversion of series C preferred stock to common stock, shares.
Beginning Balance
Temporary Equity Carrying Amount Including Portion Attributable To Noncontrolling Interests
Beginning Balance, shares
Temporary Equity Shares Outstanding
Issuance
Temporary Equity Stock Issued During Period Value New Issues
Issuance, shares
Temporary Equity Stock Issued During Period Shares New Issues
Issued on exercise of Series C Agent Warrants
Issued On Exercise Of Series C Preferred Agent Warrants
Issued on exercise of Series C Agent Warrants, shares
Issued On Exercise Of Series C Preferred Agent Warrants Shares
Conversion of series C preferred stock to common stock, shares
Conversion Of Series C Preferred Stock To Common Stock Shares
Ending Balance
Ending Balance, shares
Dividends
Dividends [Axis]
Dividends
Dividends [Domain]
Dividend payment on first anniversary.
First Anniversary [Member]
Dividend Payment On First Anniversary [Member]
Dividend payment on second anniversary.
Second Anniversary [Member]
Dividend Payment On Second Anniversary [Member]
Dividend payment on third anniversary.
Third Anniversary [Member]
Dividend Payment On Third Anniversary [Member]
Dividend payment on fourth anniversary.
Fourth Anniversary [Member]
Dividend Payment On Fourth Anniversary [Member]
Series C 3 Preferred Shares.
Series C3 Preferred Shares
Series C3 Preferred Shares [Member]
Title of Individual
Title Of Individual [Axis]
Title of Individual
Title Of Individual With Relationship To Entity [Domain]
Placement agent member.
Placement Agent
Placement Agent [Member]
Series C agent warrants.
Series C Agent Warrants [Member]
Series C Agent Warrants [Member]
Series C 1 Preferred Shares.
Series C-1 Preferred Shares [Member]
Series C1 Preferred Shares [Member]
Series C 2 Preferred Shares.
Series C-2 Preferred Shares [Member]
Series C2 Preferred Shares [Member]
Represents the entire information about agreements.
Agreements
Agreements [Axis]
Represents the entire information about agreements.
Agreements
Agreements [Domain]
Represents information about exchange agreement.
Exchange Agreement
Exchange Agreement [Member]
Pre Funded Warrants [Member]
Pre-Funded Warrants
Pre Funded Warrants [Member]
2020 Investor Warrant [Member]
Twenty Twenty Investor Warrants [Member]
Underwriter Offering.
Underwriting Offering
Underwriter Offering [Member]
Omnibus Incentive Plan [Member]
2017 Omnibus Incentive Plan [Member]
Omnibus Incentive Plan [Member]
Vesting
Vesting [Axis]
Vesting
Vesting [Domain]
Group Two [Member]
Group Two
Group Two [Member]
Director
Director [Member]
Statistical Measurement
Range [Axis]
Statistical Measurement
Range [Member]
Minimum
Minimum [Member]
Maximum
Maximum [Member]
2017 Omnibus Incentive Plan.
2017 Omnibus Incentive Plan [Member]
Two Thousand And Seventeen Omnibus Incentive Plan [Member]
Exercise Price Range
Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]
Exercise Price Range
Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]
Exercise Price Of 1.70.
Exercise Price of 1.70
Exercise Price Of One Point Seven Zero [Member]
Exercise Price Of 1.355.
Exercise Price of 1.355
Exercise Price Of One Point Three Five Five [Member]
Exercise Price of One Point Three Seven [Member]
Exercise Price Of One Point Three Seven [Member]
Executive officers and directors.
Executive Officers and Directors
Executive Officers And Directors [Member]
2017 Omnibus Incentive Plan [Member]
Two Zero One Seven Omnibus Incentive Plan [Member]
Exercise Price Of Ca [Member]
CA$ $20.00 Exercise Price
Exercise Price Of Ca [Member]
Series C Preferred Stock Warrants.
Series C Preferred Stock Warrants [Member]
Series C Preferred Stock Warrants [Member]
Measurement Input Type
Measurement Input Type [Axis]
Measurement Input Type
Measurement Input Type [Domain]
Measurement Input, Risk Free Interest Rate
Measurement Input Risk Free Interest Rate [Member]
Measurement Input, Price Volatility
Measurement Input Price Volatility [Member]
Shares issued of common stock for services
Shares issued, price per share
Shares Issued Price Per Share
Net proceeds from private placement.
Preferred stock fair value.
Proceeds from private placement
Proceeds From Issuance Of Convertible Preferred Stock
Net proceeds from private placement
Net Proceeds From Private Placement
Deferred financing costs
Payments Of Stock Issuance Costs
Stock issued during period shares new issues
Stock Issued During Period Shares New Issues
Fair value of preferred stock
Preferred Stock Fair Value
Preferred stock
Debt Instrument Convertible Conversion Price1
Conversion of stock
Conversion Of Stock Shares Issued1
Cumulative dividends
Cumulative Dividends
Number of warrants or rights outstanding, number of conversion.
10% - August 19, 2021.
10% - August 19, 2021 [Member]
Ten Percentage Nineteen August Two Thousand Twenty One [Member]
15% - August 19, 2022.
15% - August 19, 2022 [Member]
Fifteen Percentage Nineteen August Two Thousand Twenty Two [Member]
20% - August 19, 2023.
20% - August 19, 2023 [Member]
Twenty Percentage Nineteen August Two Thousand Twenty Three [Member]
25% - August 19, 2024.
25% - August 19, 2024 [Member]
Twenty Five Percentage Nineteen August Two Thousand Twenty Four [Member]
Number
Class Of Warrant Or Right Outstanding
Number of conversion shares (in thousands)
Class Of Warrant Or Right Outstanding Number Of Conversion
Dividend Shares (in thousands)
Preferred Stock Dividends Shares
Conversion of preferred stock Series B to common stock.
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]
Class of Stock [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Conversion of Series B Preferred stock to common stock
Conversion Of Preferred Stock Series Bto Commonstock
Conversion of preferred stock Series B to common stock, shares.
Conversion of Series B Preferred stock to common stock, shares
Conversion Of Preferred Stock Series Bto Commonstock Shares
Conversion of Preferred Stock to Common Stock Date
Purchase price of shares
Employee Stock Ownership Plan E S O P Weighted Average Purchase Price Of Shares Purchased
Convertible preferred stock
Convertible Preferred Stock Shares Issued Upon Conversion
Conversion Of Preferred Stock To Common Stock Date
Conversion Of Preferred Stock To Common Stock Date
Liquidation value
Preferred Stock Liquidation Preference Value
Increase (decrease) retained earnings (deficit).
Direct increase in accumulated deficit
Increase Decrease Retained Earnings Deficit
Final closing date.
Final closing date
Final Closing Date
Increase (decrease) in preferred stock.
Change in preferred stock
Increase Decrease In Preferred Stock
Common stock shares authorized
Underwritten public offering description.
Number of warrants to purchase of common stock.
Underwritten Public Offering Description
Underwritten Public Offering Description
Warrants To Purchase Common Stock
Warrants To Purchase Common Stock
Other Underwriting Expense
Other Underwriting Expense
Expiry date
Class Of Warrant Or Righst Date From Which Warrants Or Rights Exercisable
Warrants And Rights Outstanding Maturity Date
Warrants And Rights Outstanding Maturity Date
Common stock issued under 2017 plan.
Common stock, shares outstanding
Common Stock Shares Outstanding
Common stock issued under the 2017 Plan
Common Stock Issued Under2017 Plan
Pecentage of fully diluted shares of common stock.
Percentage of fully diluted shares of common stock
Fully Diluted Shares Of Common Stock Percentage
Share based compensation arrangement by share based payments award, exercise period.
Number of options granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
Exercise period
Share Based Compensation Arrangement By Share Based Payments Award Exercise Period
Total compensation expense
Allocated Share Based Compensation Expense
Stock options exercisable
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
Previous grants during the period
Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period
Accelerated vested of stock option
Sharebased Compensation Arrangement By Sharebased Payment Award Accelerated Vesting Number
Accelerated expense
Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
Stock option exercise price
Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
Share based compensation arrangements by share based payments award options vesting description.
Stock option exercise price
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
Number of options forfeited
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
Number of options expected to vest
Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
Stock option vesting description
Share Based Compensation Arrangements By Share Based Payments Award Options Vesting Description
Stock option term
Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
Beginning balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
Granted
Exercised
Forfeited
Expired
Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
Ending balance
Beginning balance
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
Granted
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
Exercised
Forfeited
Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
Expired
Share Based Compensation Arrangements By Share Based Payment Award Options Expirations In Period Weighted Average Exercise Price
Ending balance
Exercise price one.
Exercise Price One [Member]
Exercise Price One [Member]
Exercise price two.
Exercise Price Two [Member]
Exercise Price Two [Member]
Exercise price three.
Exercise Price Three [Member]
Exercise Price Three [Member]
Exercise price four.
Exercise Price Four [Member]
Exercise Price Four [Member]
Exercise price five.
Exercise Price Five [Member]
Exercise Price Five [Member]
Exercise price six.
Exercise Price Six [Member]
Exercise Price Six [Member]
Exercise price seven.
Exercise Price Seven [Member]
Exercise Price Seven [Member]
Exercise price eight.
Exercise Price Eight [Member]
Exercise Price Eight [Member]
Exercise price nine.
Exercise Price Nine [Member]
Exercise Price Nine [Member]
Exercise price ten.
Exercise Price Ten [Member]
Exercise Price Ten [Member]
Exercise price eleven.
Exercise Price Eleven [Member]
Exercise Price Eleven [Member]
Exercise price twelve.
Exercise Price Twelve [Member]
Exercise Price Twelve [Member]
Exercise price.
Exercise Price Thirteen [Member]
Exercise Price Thirteen [Member]
Exercise price.
Exercise Price Fourteen [Member]
Exercise Price Fourteen [Member]
Exercise Price Fifteen [Member]
Exercise Price Fifteen [Member]
Exercise Price Fifteen [Member]
Exercise Price Sixteen [Member]
Exercise Price Sixteen [Member]
Exercise Price Sixteen [Member]
Exercise Price Seventeen [Member]
Exercise Price Seventeen [Member]
Exercise Price Seventeen [Member]
Exercise Price Eighteen [Member]
Exercise Price Eighteen [Member]
Exercise Price Eighteen [Member]
Exercise Price Nineteen [Member]
Exercise Price Nineteen [Member]
Exercise Price Nineteen [Member]
Exercise Price Twenty [Member]
Exercise Price Twenty [Member]
Exercise Price Twenty [Member]
Exercise price twenty one.
Exercise Price Twenty One [Member]
Exercise Price Twenty One [Member]
Exercise price twenty two.
Exercise Price Twenty Two [Member]
Exercise Price Twenty Two [Member]
Exercise Price Twenty Three [Member]
Exercise Price Twenty Three [Member]
Exercise price
Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price
Number of stock options outstanding
Weighted average remaining contractual life (years)
Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
Number of stock options outstanding
Stock options exercise price
Income Statement Location
Income Statement Location [Axis]
Income Statement Location
Income Statement Location [Domain]
Research and Development [Member]
Research And Development Expense [Member]
General and Administrative [Member]
General And Administrative Expense [Member]
Unrecognized compensation expense arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
Aggregate intrinsic value of stock options outstanding
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
Aggregate intrinsic value of stock options exercisable
Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
Unrecognized compensation expense
Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
Unrecognized compensation expense, term
Unrecognized Compensation Expense Term
Beginning balance
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
Granted
Vested
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Number Of Shares
Forfeited
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares
Ending balance
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
Beginning balance
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Unvested Weighted Average Exercise Price
Granted
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Granted Weighted Average Exercise Price
Vested
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Vested Weighted Average Exercise Price
Weighted average exercise price unvested, Forfeited
Share Based Compensation Arrangement By Share Based Payment Award Stock Options Forfeited Weighted Average Exercise Price
Ending balance
Weighted average grant date fair value, Beginning balance
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
Weighted average grant date fair value, Granted
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
Weighted average grant date fair value, Vested
Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested Weighted Average Grant Date Fair Value
Weighted average grant date fair value, Forfeited
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Weighted Average Grant Date Fair Value
Weighted average grant date fair value, unvested, Ending balance
The aggregate intrinsic value of unvested stock options.
Weighted average contractual term of stock options.
Aggregate intrinsic value of unvested stock options
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Intrinsic Value
Weighted average contractual term
Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Remaining Contractual Term
Number Of Warrants Issued To Investor
Number of underwriter warrants.
Number of shares exercise of pre funded warrants.
Number of warrants exercise of investor warrants.
Warrants Issued For Services Share
Expiry of warrants for services
Issuance of Adgero warrants.
Warrant [Member]
Balance – June 30, 2019
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Outstanding Number
Underwritten public offering
Number Of Warrants Issued To Investor
Issuance of 2020 Underwriter Warrants
Number Of Underwriter Warrants
Exercise of PFW
Number Of Shares Exercise Of Pre Funded Warrants
Issuance of Adgero Warrants
Issuance Of Adgero Warrants
Exercise of 2020 Investor Warrants
Number Of Warrants Exercise Of Investor Warrants
Warrants issued for services
Warrants Issued For Services Share
Expiry of warrants issued for services
Expiry Of Warrants For Services
Balance – June 30, 2020
Exercise of warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Exercised
Expiry of warrants
Share Based Compensation Arrangement By Share Based Payment Award Non Option Equity Instruments Expirations
Share Based Compensation Arrangements by Share Based Payment Award Options Underwritten Public Offering Weighted Average Exercise Price.
Share Based Compensation Arrangements by Share Based Payment Award Options Issuance of Underwritten Warrants Weighted Average Exercise Price.
Share Based Compensation Arrangements by Share Based Payment Award Options Exercise of Pre Funded Warrants Weighted Average Exercise Price.
Share Based Compensation Arrangements by Share Based Payment Award Options Warrants Issued for Services Weighted Average Exercise Price.
Share Based Compensation Arrangements by Share Based Payment Award Options Expiry of Warrants Issued for Services Weighted Average Exercise Price.
Share Based Compensation Arrangements by Share Based Payment Award Options Issuance of Adgero Warrants Weighted Average Exercise Price.
Underwritten public offering
Share Based Compensation Arrangements By Share Based Payment Award Options Underwritten Public Offering Weighted Average Exercise Price
Issuance of 2020 Underwriter Warrants
Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Underwritten Warrants Weighted Average Exercise Price
Exercise of PFW
Share Based Compensation Arrangements By Share Based Payment Award Options Exercise Of Pre Funded Warrants Weighted Average Exercise Price
Issuance of Adgero Warrants
Share Based Compensation Arrangements By Share Based Payment Award Options Issuance Of Adgero Warrants Weighted Average Exercise Price
Warrants issued for services
Share Based Compensation Arrangements By Share Based Payment Award Options Warrants Issued For Services Weighted Average Exercise Price
Expiry of warrants issued for services
Share Based Compensation Arrangements By Share Based Payment Award Options Expiry Of Warrants Issued For Services Weighted Average Exercise Price
Number of warrants exercise of investor warrants for cash.
Investor warrants exercised
Number Of Warrants Exerciseof Investor Warrants For Cash
Warrants exercise price
Number of common shares called by warrants exercise
Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
Related Party
Related Party Transactions By Related Party [Axis]
Related Party
Related Party [Domain]
Investor one member.
Investor One [Member]
Investor One [Member]
Investor two member.
InvestorTwo [Member]
Investor Two [Member]
Investor three member.
InvestorThree [Member]
Investor Three [Member]
Investor Four [Member]
Investor Four
Investor Four [Member]
NBTS.
NBTS [Member]
N B T S [Member]
Agent [Member]
Agent [Member]
Agent [Member]
Agent One [Member]
Agent One [Member]
Agent One [Member]
Agent Two [Member]
Agent Two [Member]
Agent Two [Member]
Adgero Warrants One.
Adgero Warrants One
Adgero Warrants One [Member]
Adgero Warrants Two [Member]
Adgero Warrants Two
Adgero Warrants Two [Member]
Industry Sector
Equity Securities By Industry [Axis]
Industry Sector
Equity Securities Industry [Member]
Issued For Services One [Member]
Issued For Services One [Member]
Issued For Services One [Member]
Issued For Services Two [Member]
Issued For Services Two [Member]
Issued For Services Two [Member]
Issued For Services Three [Member]
Issued For Services Three [Member]
Issued For Services Three [Member]
Issued For Services Four [Member]
Issued For Services Four [Member]
Issued For Services Four [Member]
Issued For Services Five [Member]
Issued For Services Five [Member]
Issued For Services Five [Member]
Issued for services six.
Issued For Services Six [Member]
Issued For Services Six [Member]
Issued for services seven.
Issued For Services Seven [Member]
Issued For Services Seven [Member]
Issued for services eight
Issued For Services Eight [Member]
Issued For Services Eight [Member]
Issued for services nine
Issued For Services Nine [Member]
Issued For Services Nine [Member]
Issued for services ten
Issued For Services Ten [Member]
Issued For Services Ten [Member]
Issued for services eleven.
Issued For Services Eleven [Member]
Issued For Services Eleven [Member]
Fair value disclosure
Equity Fair Value Disclosure
Warrants outstanding, measurement input
Warrants And Rights Outstanding Measurement Input
Warrants outstanding, term
Warrants And Rights Outstanding Term
Number of warrants issued.
Class of warrant or right number of warrants or rights exercised.
Issuance of Preferred Series C-1 Warrants.
Issuance of Preferred Series C-1 Agent Warrants [Member]
Issuance Of Preferred Series C1 Warrants [Member]
Issuance of Preferred Series C-2 Warrants.
Issuance of Preferred Series C-2 Agent Warrants [Member]
Issuance Of Preferred Series C2 Warrants [Member]
Issuance of Preferred Series C-3 Warrants.
Issuance of Preferred Series C-3 Agent Warrants [Member]
Issuance Of Preferred Series C3 Warrants [Member]
Balance
Number of Warrants Issued
Number Of Warrants Issued
Number of Warrants Exercised
Class Of Warrant Or Right Number Of Warrants Or Rights Exercised
Balance
Series 1 Warrants Outstanding.
Series 1 Warrants Outstanding
Series1 Warrants Outstanding [Member]
Series 2 warrants Outstanding.
Series 2 Warrants Outstanding Member
Series2 Warrants Outstanding [Member]
Series 3 Warrants Outstanding.
Series 3 Warrants Outstanding
Series3 Warrants Outstanding [Member]
Cumulative common stock dividends (in thousands)
Common Stock Dividends Shares
Deferred tax assets financing cost.
Deferred tax liabilities scientific research and development.
Components Of Deferred Tax Assets [Abstract]
Deferred tax assets:
Deferred Tax Assets Net [Abstract]
Non-capital losses carried forward
Deferred Tax Assets Operating Loss Carryforwards
Stock-based compensation
Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
Capital losses carried forward
Deferred Tax Assets Capital Loss Carryforwards
Financing costs
Deferred Tax Assets Financing Cost
Scientific research and development
Deferred Tax Assets In Process Research And Development
Scientific research and development – Investment Tax Credits (“ITC”)
Deferred Tax Assets Tax Credit Carryforwards Research
Deferred tax assets
Deferred Tax Assets Liabilities Net
Deferred tax liabilities:
Deferred Tax Liabilities Classification [Abstract]
Scientific research and development – ITC
Deferred Tax Liabilities Scientific Research And Development
Gross future tax assets
Deferred Tax Assets Gross
Valuation allowance
Deferred Tax Assets Valuation Allowance
Net future tax assets
Deferred Tax Assets Net
Current And Future Income Taxes Textuals [Abstract]
Tax Credit Carryforward [Table]
Tax Credit Carryforward [Table]
Geographical
Statement Geographical [Axis]
Geographical
Segment Geographical [Domain]
United States [Member]
UNITED STATES
Us And Canadian [Member]
US and Canadian [Member]
Us And Canadian [Member]
Canadian [Member]
CANADA
Columbia [Member]
British Columbia [Member]
Columbia [Member]
Canadian Scientific Research And Development [Member]
Canadian Scientific Research and Development [Member]
Canadian Scientific Research And Development [Member]
Tax Credit Carryforward [Line Items]
Tax Credit Carryforward [Line Items]
Current and Future Income Taxes (Textual)
Current And Future Income Taxes Textuals [Abstract]
Statutory income tax rate
Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
Income tax reconciliation permanent differences.
Income tax reconciliation effect of foreign exchange rates.
Income tax reconciliation non-capital losses acquired.
Income Tax Reconciliation Nondeductible Expense (Benefit) Research And Development.
Income tax reconciliation adjustment to prior year's provision versus statutory tax returns.
Effective income tax rate differs from the statutory income tax rate
Income Tax Expense Benefit Continuing Operations Income Tax Reconciliation [Abstract]
Tax recovery at statutory income tax rates
Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate
Permanent differences
Income Tax Reconciliation Permanent Differences
Effect of rate differentials between jurisdictions
Income Tax Reconciliation Foreign Income Tax Rate Differential
Effect of foreign exchange rates
Income Tax Reconciliation Effect Of Foreign Exchange Rates
Non-capital losses acquired with Adgero
Income Tax Reconciliation Non Capital Losses Acquired
Scientific research and development – ITC
Income Tax Reconciliation Nondeductible Expense Benefit Research And Development
Adjustment to prior year's provision versus statutory tax returns
Income Tax Reconciliation Adjustment To Prior Year S Provision Versus Statutory Tax Returns
Change in valuation allowance
Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance
Income tax expense benefit
Income Tax Expense Benefit
The percentage of taxable income that the net operating loss carryforwards can not exceed.
Loss before income taxes
Income Loss From Continuing Operations Before Income Taxes Foreign
Operating loss carryforwards
Operating Loss Carryforwards
Net operating loss expire, description
Operating Loss Carryforwards Limitations On Use
Deferred tax assets, Operating loss carryforwards, Not subject to expiration
Deferred Tax Assets Operating Loss Carryforwards Not Subject To Expiration
Percentage of taxable income, limitation on NOLs
Percentage Of Taxable Income Limitation On N O Ls
Non-refundable federal investment tax credits
Investment Tax Credit
Investment tax credits expire, description
Tax Credit Carryforward Description
Current income tax expense (benefit)
Current Income Tax Expense Benefit
Open tax years
Open Tax Year
Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax.
Cumulative change in ownership period.
Represents minimum cumulative percentage of change in ownership as a condition to offset taxable income or tax
Minimum Cumulative Percentage Of Change In Ownership As Condition To Offset Taxable Income Or Tax
Cumulative change in ownership period
Cumulative Change In Ownership Period
Manufacturing And Clinical Study Management Related Cost
Clinical Development Research Deposits
Commitments And Contingencies Textual [Abstract]
Loss Contingencies [Table]
Loss Contingencies [Table]
Currency
Currency [Axis]
All Currencies
All Currencies [Domain]
CAD [Member]
C A D
Head office.
Head Office [Member]
Head Office [Member]
Administrative offices.
Administrative Offices [Member]
Administrative Offices [Member]
Loss Contingencies [Line Items]
Loss Contingencies [Line Items]
Commitments and Contingencies (Textual)
Commitments And Contingencies Textual [Abstract]
Manufacturing and clinical study management related cost
Manufacturing And Clinical Study Management Related Cost
Deposits related to study initiation
Clinical Development Research Deposits
Periodic Lease Rent Payment
Periodic lease rent term.
Lease rent for office space term
Periodic Lease Rent Term
Lease rent for office space
Periodic Lease Rent Payment
Rent expense
Lease And Rental Expense
The fair value of issuance cost in noncash investing and financing activities.
Deferred costs in accounts payable.
Warrants issued as deferred costs.
Cashless exercise of warrants.
Conversion of Series B Preferred stock shares to common stock.
Supplemental cash flow elements line items.
Supplemental cash flow elements table.
Supplemental Cash Flow Elements [Table]
Supplemental Cash Flow Elements [Table]
Supplemental Cash Flow Elements [Line Items]
Supplemental Cash Flow Elements [Line Items]
Supplemental Cash Flow Information [Abstract]
Supplemental Cash Flow Information [Abstract]
Series B Preferred Stock common stock dividend (note 8)
Deemed dividend recognized on beneficial conversion features of Series C Preferred stock issuance (note 8)
Non-cash issue costs (note 8)
Non Cash Issue Costs
Deferred costs in accounts payable
Deferred Costs In Accounts Payable
Warrants issued as deferred costs (note 7)
Warrants Issued As Deferred Costs
Cashless exercise of warrants
Cashless Exercise Of Warrants
Conversion of Series B Preferred Stock to common stock (note 8)
Conversion Of Series B Preferred Stock Shares To Common Stock
Conversion of Series C Preferred Stock to common stock (note 8)
Income taxes paid
Income Taxes Paid Net
Interest paid
Interest Paid Net
Foreign Currency Fair Value Hedge Derivative [Table]
Foreign Currency Fair Value Hedge Derivative [Table]
Trading Activity
Trading Activity By Type [Axis]
Trading Activity, by Type
Trading Activity By Type [Domain]
Foreign exchange risk [Member]
Foreign Exchange [Member]
Servicing Assets and Servicing Liabilities Risk
Managing Risks Inherent In Servicing Assets And Servicing Liabilities By Type Of Risk [Axis]
Risks Inherent in Servicing Assets and Servicing Liabilities, Type
Risks Inherent In Servicing Assets And Servicing Liabilities Type [Domain]
Liquidity Risk [Member]
Liquidity Risk [Member]
Liquidity Risk [Member]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Foreign Currency Fair Value Hedge Derivative [Line Items]
Financial risk, accounts payable and accrued liabilities
Accounts Payable And Accrued Liabilities Current And Noncurrent
Foreign exchange risk maximum exposure.
Maximum exposure of financial currency due to exchange rates, description
Description Of Foreign Currency Exposure
Foreign exchange risk maximum exposure
Foreign Exchange Risk Maximum Exposure
Trade payables
Accounts Payable Trade Current And Noncurrent
Cash
Cash
Interest, taxes, and other receivables
Interest Receivable And Other Assets
Maximum exposure of interest rate risk, description
Description Of Interest Rate Risk Exposure
Liquidity Risk Maximum Exposure
Liquidity risk maximum exposure
Liquidity Risk Maximum Exposure
Concentration risk credit risk uninsured amount of cash.
Credit risk, financial instrument maximum exposure
Concentration Risk Credit Risk Financial Instrument Maximum Exposure
Credit risk, uninsured cash and cash equivalents
Concentration Risk Credit Risk Uninsured Amount Of Cash
Insured amount $
Cash F D I C Insured Amount
Non- insured amount $
Cash Uninsured Amount
Investor warrants exercisable period, description.
Subsequent Event [Table]
Subsequent Event [Table]
Subsequent Event Type
Subsequent Event Type [Axis]
Subsequent Event Type
Subsequent Event Type [Domain]
Subsequent Event [Member]
Subsequent Event [Member]
Agent warrants.
Agent Warrant [Member]
Agent Warrant [Member]
Derivative Instrument
Derivative Instrument Risk [Axis]
Derivative Contract
Derivative Contract Type [Domain]
Stock Option [Member]
Stock Option [Member]
Subsequent Event [Line Items]
Subsequent Event [Line Items]
Gross proceeds
Proceeds From Issuance Of Common Stock
Investor warrants exercisable period, description
Investor Warrants Exercisable Period Description
Dividend rate percentage payment.
Common stock shares accrued.
Dividends payable
Dividend Rate Percentage Payment
Common stock shares accrued
Common Stock Shares Accrued
Number of warrant or right exercised.
Class of warrant or right expired during period
Class of warrant expired or right exercise price of warrants or rights 1
Number of warrants exercised
Class Of Warrant Or Right Exercised
Warrants issued
Class Of Warrant Or Right Expired During Period
Warrants exercise price expired
Class Of Warrant Expired Or Right Exercise Price Of Warrants Or Rights1
Stock option commencing date description.
Stock option exercise period
Share Based Compensation Arrangement By Share Based Payment Award Expiration Date
Stock option commencing date, Description
Stock Option Commencing Date Description